The current antipsychotic therapeutic potential of A1R agonists and A2AR antagonists in schizophrenia is largely based on preclinical models and theoretical considerations; however, further studies investigating the underlying molecular basis for these considerations such as those examined in the present study, and, of course, clinical evidence, have yet to be established [8,22]. The gene discussed is ADORA2A; the disease is schizophrenia.